Hubei Bio-Pharmaceutical Industrial Technological Institute discloses new LPAM-1 antagonists

July 22, 2026

Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. has patented integrin α4β7 (LPAM-1) antagonists that are potentially useful for the treatment of autoimmune disease, ulcerative colitis and Crohn’s disease.

BioWorld Science Immune Patents

Today's news in brief

BioWorld

BioWorld briefs for July 24, 2026.

To viral or not to viral: In vivo CAR T debates delivery tech

BioWorld

The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 21, 2026

Tree in the shape of human head losing leaves

KBN-2201 reverses key features of Alzheimer’s in mice

BioWorld Science

Researchers from Ajou University School of Medicine reported the preclinical efficacy of KBN-2201 in a mouse model of late-stage Alzheimer’s disease.

To viral or not to viral: In vivo CAR T debates delivery tech

BioWorld Science

The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...